Alto Neuroscience Inc (ANRO)

$35.68 +0.13 (0.37%)
Market Cap 1.40B
Revenue (ttm) 0.00
Net Income (ttm) -63.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 255,235
Avg Vol 585,266
Day's Range N/A - N/A
Shares Out 39.24M
Stochastic %K 45%
Beta 1.13
Analysts Strong Sell
Price Target $37.67

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
BossTrade
BossTrade Aug. 26 at 6:56 PM
$CAPR I invite everyone to look at my other call $ANRO Before yall trash talk thanx
1 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Aug. 26 at 4:04 PM
$ANRO $SLS and coming soon to $CING and $PYPD
0 · Reply
Ccperk
Ccperk Aug. 24 at 9:19 PM
$ANRO Still looks like $50 by 2027. I’m sort of speechless at this point. I sold some but holding some covered calls. GLTA besides shorts
0 · Reply
XQuise
XQuise Aug. 24 at 7:12 PM
$ANRO 😘
1 · Reply
XQuise
XQuise Aug. 24 at 7:08 PM
$ANRO Wow, that’s really impressive! That kind of growth in just a year... I’m especially happy for those who held on here for so long! Congratulations! I definitely sold too early 🤭
0 · Reply
DanFitz
DanFitz Aug. 17 at 11:15 PM
Here's your 1-2-3- trade on Alto Neuroscience $ANRO https://youtu.be/9lxnPH8JTlA
0 · Reply
Chi_ho
Chi_ho Aug. 17 at 2:37 PM
$ANRO have been satisfied with this but difficult to determine its potential headwinds that could derail it’s momentum through end of year. Purely technical or is its product queue that hot?
0 · Reply
Dogster304
Dogster304 Aug. 13 at 8:19 PM
$ANRO I fucking love this stock been in it since $5
0 · Reply
anachartanalyst
anachartanalyst Aug. 13 at 11:01 AM
$ANRO https://anachart.com/wp-content/uploads/2026/08/1786618882_soc-img.jpg
0 · Reply
fda_tracker
fda_tracker Aug. 5 at 3:04 PM
$ANRO Phase 2 trial w/est Aug completion date NCT06656416: https://www.clinicaltrials.gov/study/NCT06656416 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Latest News on ANRO
Alto Neuroscience names Nick Smith president, CFO

2026-08-27T20:15:35.000Z - 11 days ago

Alto Neuroscience names Nick Smith president, CFO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Aug 27, 2026, 4:05 PM EDT - 11 days ago

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright

2026-08-17T15:30:08.000Z - 22 days ago

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright

Alto Neuroscience reports Q EPS (65c), consensus (77c)

2026-08-17T08:53:48.000Z - 22 days ago

Alto Neuroscience reports Q EPS (65c), consensus (77c)

Alto Neuroscience price target raised to $37 from $28 at BTIG

2026-08-17T08:08:59.000Z - 22 days ago

Alto Neuroscience price target raised to $37 from $28 at BTIG

Alto Neuroscience price target raised to $37 from $33 at BofA

2026-08-16T13:30:21.000Z - 23 days ago

Alto Neuroscience price target raised to $37 from $33 at BofA

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 12, 2026, 4:03 PM EDT - 26 days ago

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 26 days ago

Alto Neuroscience Earnings release: Q2 2026

Alto Neuroscience Quarterly report: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 26 days ago

Alto Neuroscience Quarterly report: Q2 2026

Alto Neuroscience Slides: Corporate presentation

Aug 12, 2026, 7:00 AM EDT - 27 days ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering

2026-07-13T11:56:00.000Z - 1 month ago

Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Jul 13, 2026, 7:47 AM EDT - 1 month ago

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

2026-06-15T12:16:21.000Z - 2 months ago

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Jun 15, 2026, 8:03 AM EDT - 2 months ago

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience Slides: Corporate presentation

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 3 months ago

Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026

Alto Neuroscience appoints Miller to Board of Directors

2026-05-28T12:48:57.000Z - 3 months ago

Alto Neuroscience appoints Miller to Board of Directors

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

May 28, 2026, 8:03 AM EDT - 3 months ago

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Alto Neuroscience price target lowered to $33 from $35 at BofA

2026-05-22T11:55:51.000Z - 3 months ago

Alto Neuroscience price target lowered to $33 from $35 at BofA

Alto Neuroscience price target lowered to $36 from $38 at Baird

2026-05-18T11:43:06.000Z - 3 months ago

Alto Neuroscience price target lowered to $36 from $38 at Baird

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

May 15, 2026, 8:27 AM EDT - 3 months ago

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience price target raised to $24 from $21 at Wedbush

2026-05-14T17:24:06.000Z - 3 months ago

Alto Neuroscience price target raised to $24 from $21 at Wedbush

Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:15 PM EDT - 3 months ago

Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026

Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year

2026-05-13T13:07:17.000Z - 3 months ago

Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 7:03 AM EDT - 3 months ago

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Alto Neuroscience Earnings release: Q1 2026

Alto Neuroscience Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Alto Neuroscience Quarterly report: Q1 2026

Alto Neuroscience Slides: Corporate presentation

May 11, 2026, 6:00 PM EDT - 3 months ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

May 11, 2026, 4:05 PM EDT - 3 months ago

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience initiated with a Buy at BofA

2026-05-04T20:26:52.000Z - 4 months ago

Alto Neuroscience initiated with a Buy at BofA

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

2026-05-04T12:31:04.000Z - 4 months ago

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

May 4, 2026, 8:03 AM EDT - 4 months ago

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

Alto Neuroscience participates in a conference call with H. C. Wainwright

2026-04-29T17:18:32.000Z - 4 months ago

Alto Neuroscience participates in a conference call with H. C. Wainwright

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD

2026-04-21T13:15:23.000Z - 4 months ago

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Apr 21, 2026, 8:03 AM EDT - 4 months ago

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience files to sell 6M shares of common stock for holders

2026-04-10T20:05:23.000Z - 5 months ago

Alto Neuroscience files to sell 6M shares of common stock for holders

Alto Neuroscience Registration statement: Registration filing

Apr 10, 2026, 8:00 AM EDT - 5 months ago

Alto Neuroscience Registration statement: Registration filing

Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright

2026-04-02T16:29:46.000Z - 5 months ago

Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright

Alto Neuroscience price target lowered to $21 from $22 at Wedbush

2026-04-02T13:05:12.000Z - 5 months ago

Alto Neuroscience price target lowered to $21 from $22 at Wedbush

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Apr 1, 2026, 4:30 PM EDT - 5 months ago

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Alto Neuroscience Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alto Neuroscience Proxy statement: Proxy filing

Alto Neuroscience Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alto Neuroscience Proxy statement: Proxy filing

Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 12:00 PM EDT - 5 months ago

Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum

Alto Neuroscience Announces $120 Million Private Placement Financing

Mar 16, 2026, 7:03 AM EDT - 5 months ago

Alto Neuroscience Announces $120 Million Private Placement Financing

Alto Neuroscience Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Earnings release: Q4 2025

Alto Neuroscience Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Annual report: Q4 2025

Alto Neuroscience Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 16, 2026, 6:03 AM EDT - 5 months ago

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Mar 13, 2026, 8:03 AM EDT - 5 months ago

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:50 PM EST - 6 months ago

Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Feb 13, 2026, 8:04 AM EST - 6 months ago

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Feb 3, 2026, 8:27 AM EST - 7 months ago

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Jan 14, 2026, 7:27 AM EST - 7 months ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Jan 13, 2026, 8:00 AM EST - 7 months ago

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Alto Neuroscience Slides: Corporate presentation

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Dec 3, 2025, 4:05 PM EST - 9 months ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto Neuroscience Registration statement: Registration Filing

Nov 28, 2025, 7:00 AM EST - 9 months ago

Alto Neuroscience Registration statement: Registration Filing

Alto Neuroscience Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 10:30 AM EST - 9 months ago

Alto Neuroscience Transcript: Jefferies London Healthcare Conference 2025

Alto Neuroscience Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 10 months ago

Alto Neuroscience Transcript: Stifel 2025 Healthcare Conference

Alto Neuroscience Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Alto Neuroscience Quarterly report: Q3 2025

Alto Neuroscience Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Alto Neuroscience Earnings release: Q3 2025

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:57 AM EST - 10 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:34 AM EDT - 10 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 10 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 10 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 11 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 11 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 11 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 1:20 PM EDT - 11 months ago

Alto Neuroscience Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Alto Neuroscience Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 2:00 PM EDT - 12 months ago

Alto Neuroscience Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 12 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 1 year ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 1 year ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Quarterly report: Q2 2025

Alto Neuroscience Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Earnings release: Q2 2025

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 1 year ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

BossTrade
BossTrade Aug. 26 at 6:56 PM
$CAPR I invite everyone to look at my other call $ANRO Before yall trash talk thanx
1 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Aug. 26 at 4:04 PM
$ANRO $SLS and coming soon to $CING and $PYPD
0 · Reply
Ccperk
Ccperk Aug. 24 at 9:19 PM
$ANRO Still looks like $50 by 2027. I’m sort of speechless at this point. I sold some but holding some covered calls. GLTA besides shorts
0 · Reply
XQuise
XQuise Aug. 24 at 7:12 PM
$ANRO 😘
1 · Reply
XQuise
XQuise Aug. 24 at 7:08 PM
$ANRO Wow, that’s really impressive! That kind of growth in just a year... I’m especially happy for those who held on here for so long! Congratulations! I definitely sold too early 🤭
0 · Reply
DanFitz
DanFitz Aug. 17 at 11:15 PM
Here's your 1-2-3- trade on Alto Neuroscience $ANRO https://youtu.be/9lxnPH8JTlA
0 · Reply
Chi_ho
Chi_ho Aug. 17 at 2:37 PM
$ANRO have been satisfied with this but difficult to determine its potential headwinds that could derail it’s momentum through end of year. Purely technical or is its product queue that hot?
0 · Reply
Dogster304
Dogster304 Aug. 13 at 8:19 PM
$ANRO I fucking love this stock been in it since $5
0 · Reply
anachartanalyst
anachartanalyst Aug. 13 at 11:01 AM
$ANRO https://anachart.com/wp-content/uploads/2026/08/1786618882_soc-img.jpg
0 · Reply
fda_tracker
fda_tracker Aug. 5 at 3:04 PM
$ANRO Phase 2 trial w/est Aug completion date NCT06656416: https://www.clinicaltrials.gov/study/NCT06656416 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
BioTuesdays
BioTuesdays Aug. 4 at 1:03 PM
$ANRO is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven pipeline designed to deliver more effective treatment options. Drawing on expertise in central nervous system (CNS) drug development and commercialization, the company is seeking to move psychiatry beyond its traditional trial-and-error approach. https://biotuesdays.com/2026/08/04/alto-disrupting-the-trial-and-error-approach-to-treating-neuropsychiatric-disorders/
0 · Reply
Dogster304
Dogster304 Jul. 31 at 10:38 AM
$ANRO been with this beauty since it was $5 a share
0 · Reply
TripleWitch
TripleWitch Jul. 14 at 1:44 AM
$ANRO $PSNL You must mean the one that did the after hours equity offering, no? 🤷‍♂️
0 · Reply
RunnerSignals
RunnerSignals Jul. 13 at 7:53 PM
red to green $PSNL and $ANRO flipped the script into the close, but one reversal had the cleaner volume signature. traders may be watching the wrong winner
0 · Reply
focafoca99
focafoca99 Jul. 13 at 12:12 PM
$ANRO estimated its cash, cash equivalents and restricted cash at about $244.2 million as of June 30, 2026.
0 · Reply
FaithFilledTrader
FaithFilledTrader Jul. 13 at 11:44 AM
$ANRO news
0 · Reply
DiamondHandsJimbo
DiamondHandsJimbo Jul. 10 at 5:59 PM
$ANRO 😝🔥🚀
0 · Reply
DiamondHandsJimbo
DiamondHandsJimbo Jul. 10 at 4:43 PM
$ANRO show me some green LMAO… Entry at $26.14 🤞🚀
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:57 PM
$RILY $SLS $ANRO $OUST $POET The other half of that message from one year ago. What do you guys have planned for the next year? I guess, more importantly... What do WE have planned for next year?
3 · Reply
Ccperk
Ccperk Jun. 26 at 7:48 PM
$ANRO not exactly sure what’s going on here. Partnership or buyout imminent? Who knows
0 · Reply
MrGreenth
MrGreenth Jun. 23 at 6:06 PM
$ANRO 30$ next up
0 · Reply
focafoca99
focafoca99 Jun. 15 at 12:32 PM
$ANRO showed significant anhedonia reduction in a Nature Medicine study of pramipexole.
0 · Reply